J D Lundgren

Summary

Affiliation: Hvidovre University Hospital
Country: Denmark

Publications

  1. pmc Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study
    Daria N Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    BMC Infect Dis 12:229. 2012
  2. pmc When to start antiretroviral therapy: the need for an evidence base during early HIV infection
    Jens D Lundgren
    Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
    BMC Med 11:148. 2013
  3. pmc Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods
    Alison Rodger
    Research Department of Infection and Population Health, University College London, London, UK
    BMC Public Health 12:296. 2012
  4. pmc Procalcitonin in liver transplant patients--yet another stone turned
    Jens Ulrik Jensen
    Crit Care 12:108. 2008
  5. pmc In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging
    Christian T Brandt
    National Center for Antimicrobials and Infection Control, Statens Serum Institut, Copenhagen, Denmark
    BMC Med Imaging 8:1. 2008
  6. pmc The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, ca
    Jens Ulrik Jensen
    Dept Of Clinical Microbiology 445, Hvidovre Hospital, Kettegard Alle 30, DK 2650, Hvidovre, Denmark
    BMC Infect Dis 8:91. 2008
  7. ncbi request reprint A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study
    Jens D Lundgren
    EuroSIDA Copenhagen HIV Programme Coordinating Centre, Dept of Infectious Diseases, Hvidovre University Hospital, 2650 Hvidovre, Denmark
    J Infect Dis 185:178-87. 2002
  8. ncbi request reprint Anemia and survival in human immunodeficiency virus
    Jens D Lundgren
    Copenhagen HIV Programme 044, Hvidovre University Hospital, Hvidovre, Denmark
    Clin Infect Dis 37:S297-303. 2003
  9. ncbi request reprint The impact of antiretroviral therapy on AIDS and survival
    Jens D Lundgren
    Hvidovre University Hospital, Denmark
    J HIV Ther 11:36-8. 2006
  10. doi request reprint European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV
    J D Lundgren
    Centre for Viral Diseases KMA, Rigshospitalet and Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    HIV Med 9:72-81. 2008

Detail Information

Publications102 found, 100 shown here

  1. pmc Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study
    Daria N Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    BMC Infect Dis 12:229. 2012
    ..State-of-the-art care involving the utilisation of multiple health care interventions is the basis for an optimal long-term clinical prognosis for HIV-patients. We evaluated health care for HIV patients based on four key indicators...
  2. pmc When to start antiretroviral therapy: the need for an evidence base during early HIV infection
    Jens D Lundgren
    Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
    BMC Med 11:148. 2013
    ....
  3. pmc Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods
    Alison Rodger
    Research Department of Infection and Population Health, University College London, London, UK
    BMC Public Health 12:296. 2012
    ..There are no data on risk of transmission for anal sex in MSM when the index partner is on ART...
  4. pmc Procalcitonin in liver transplant patients--yet another stone turned
    Jens Ulrik Jensen
    Crit Care 12:108. 2008
    ..This new information gives us hope that procalcitonin can be used as a marker of bacterial infection in these patients. Further studies of patients undergoing liver transplantation with and without bacterial infection are needed...
  5. pmc In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging
    Christian T Brandt
    National Center for Antimicrobials and Infection Control, Statens Serum Institut, Copenhagen, Denmark
    BMC Med Imaging 8:1. 2008
    ..The identification and characterisation of pathophysiological parameters that vary during the course of the disease could be used as markers for future studies of new treatment strategies...
  6. pmc The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, ca
    Jens Ulrik Jensen
    Dept Of Clinical Microbiology 445, Hvidovre Hospital, Kettegard Alle 30, DK 2650, Hvidovre, Denmark
    BMC Infect Dis 8:91. 2008
    ..At the same time, lack of a relevant antimicrobial therapy in an early course of infection may be fatal for the patient. Specific and rapid markers of bacterial infection have been sought for use in these patients...
  7. ncbi request reprint A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study
    Jens D Lundgren
    EuroSIDA Copenhagen HIV Programme Coordinating Centre, Dept of Infectious Diseases, Hvidovre University Hospital, 2650 Hvidovre, Denmark
    J Infect Dis 185:178-87. 2002
    ..38; 95% confidence interval, 1.33-1.43; P<.0001). The scoring system was validated with remarkably good agreement in the 2 other cohorts. This system can be used in patient and resource management...
  8. ncbi request reprint Anemia and survival in human immunodeficiency virus
    Jens D Lundgren
    Copenhagen HIV Programme 044, Hvidovre University Hospital, Hvidovre, Denmark
    Clin Infect Dis 37:S297-303. 2003
    ..5-20.1), respectively, compared with patients with no anemia. The mechanisms underlying why hemoglobin is such a strong prognostic marker and whether correction of anemia itself results in a better prognosis remain to be determined...
  9. ncbi request reprint The impact of antiretroviral therapy on AIDS and survival
    Jens D Lundgren
    Hvidovre University Hospital, Denmark
    J HIV Ther 11:36-8. 2006
  10. doi request reprint European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV
    J D Lundgren
    Centre for Viral Diseases KMA, Rigshospitalet and Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    HIV Med 9:72-81. 2008
    ..Metabolic diseases are frequently observed in HIV-infected persons and, as the risk of contracting these diseases is age-related, their prevalence will increase in the future as a consequence of the benefits of antiretroviral therapy (ART)...
  11. doi request reprint Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  12. pmc Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs
    Jens D Lundgren
    Copenhagen HIV Programme, Section 044, Hvidovre University Hospital, 2650 Hvidovre, Denmark
    BMJ 328:253. 2004
  13. ncbi request reprint The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study
    S Jensen-Fangel
    Department of Infectious Diseases, Marselisborg Hospital, Aarhus University Hospital, Denmark
    HIV Clin Trials 2:122-7. 2001
    ..To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc)...
  14. ncbi request reprint Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir
    O Kirk
    EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
    AIDS 15:999-1008. 2001
    ..To compare the clinical response among patients who initiate protease inhibitor therapies with different virological potency...
  15. ncbi request reprint The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
    T L Katzenstein
    Department of Infectious Disease, Rigshospitalet, 2100 O Copenhagen, Denmark
    J Infect Dis 182:744-50. 2000
    ....
  16. ncbi request reprint Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia
    J Helweg-Larsen
    Department of Infectious Diseases, University of Copenhagen, Hvidovre Hospital, Denmark
    Lancet 354:1347-51. 1999
    ..We assessed whether mutations in the DHPS gene of P. carinii were associated with exposure to sulpha drugs and influenced outcome from PCP...
  17. ncbi request reprint Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort
    O Kirk
    Departments of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    HIV Med 2:43-51. 2001
    ..To assess predictors for discontinuation and treatment-limiting adverse drug reactions (TLADR) among patients starting their first protease inhibitor (PI)...
  18. doi request reprint Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir
    J D Kowalska
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    HIV Med 11:200-8. 2010
    ..The number needed to harm (NNH) incorporates information about the underlying risk of MI and the increased RR of MI in patients taking abacavir...
  19. ncbi request reprint Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine
    Jan Gerstoft
    Department of Infectious Diseases at Rigshospitalet, Copenhagen, Denmark
    AIDS 17:2045-52. 2003
    ..Highly active antiretroviral therapy containing three nucleoside reverse transcriptase inhibitors has been somewhat successful, but the clinical efficacy is unclear...
  20. ncbi request reprint Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death
    C Holkmann Olsen
    Copenhagen HIV Programme, Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
    HIV Med 8:96-104. 2007
    ....
  21. doi request reprint Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe
    L Ryom
    Copenhagen HIV Programme, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    HIV Med 14:503-8. 2013
    ..Knowledge about advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) in HIV-positive persons is limited. The aim of this study was to investigate incidence, predictors and outcomes for advanced CKD/ESRD and renal death...
  22. pmc Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
    Zoe Fox
    Copenhagen HIV Programme, University of Copenhagen Rigshospitalet, Copenhagen, Denmark
    AIDS 22:2279-89. 2008
    ..Limited data exist to guide clinical practice on the best interruption strategy to use...
  23. ncbi request reprint Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group
    J D Lundgren
    University of Copenhagen, Hvidovre Hospital, Denmark
    J Acquir Immune Defic Syndr Hum Retrovirol 16:153-60. 1997
    ..U.S. recommendations on the use of antimycobacterial prophylaxis have not been implemented in Europe...
  24. ncbi request reprint Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia
    T L Benfield
    Department of Infectious Diseases, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark
    Chest 119:844-51. 2001
    ..We hypothesized that the natural course of AIDS-associated PCP has changed in the era of adjunctive corticosteroid therapy...
  25. ncbi request reprint Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f.sp. hominis
    J Helweg-Larsen
    Department of Infectious Diseases, Hvidovre Hospital, 2650 Hvidovre, Denmark
    AIDS 15:451-9. 2001
    ..To analyse the importance of sequence variations in the internal transcribed spacer (ITS) regions 1 and 2 of the nuclear rRNA operon in AIDS patients with Pneumocystis carinii pneumonia (PCP)...
  26. ncbi request reprint Class of antiretroviral drugs and the risk of myocardial infarction
    Nina Friis-Møller
    University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 356:1723-35. 2007
    ..We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction...
  27. doi request reprint The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology
    Justyna D Kowalska
    Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Epidemiology 22:516-23. 2011
    ..The Coding Causes of Death in HIV (CoDe) Project aims to deliver a standardized method for coding the underlying cause of death in HIV-positive persons, suitable for clinical trials and epidemiologic studies...
  28. pmc The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes
    T L Benfield
    Department of Infectious Diseases, University of Copenhagen, Hvidovre Hospital, Denmark
    Infect Immun 65:4790-4. 1997
    ..These data show that recognition of MSG by monocytes involves a mannose-mediated mechanism and results in the release of the proinflammatory cytokines IL-8 and TNF-alpha...
  29. ncbi request reprint The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors
    Zoe V Fox
    Copenhagen HIV Programme, Medical Faculty at University of Copenhagen, Denmark
    AIDS 21:2033-42. 2007
    ..We compared PI/r resistance levels ascribed by four GIS and examined their abilities to predict HIV-RNA reductions after starting a PI/r-based regimen (baseline)...
  30. ncbi request reprint Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2
    Zoe Fox
    Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
    HIV Med 8:112-23. 2007
    ..The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks)...
  31. doi request reprint High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome
    Signe W Worm
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    AIDS 24:427-35. 2010
    ....
  32. ncbi request reprint A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial
    Zoe Fox
    Copenhagen HIV Programme CHIP, Hvidovre University Hospital, Copenhagen, Denmark
    Antivir Ther 11:761-70. 2006
    ..No data exist from clinical comparative studies evaluating the benefit of M1841/V in patients receiving combination antiretroviral therapy (cART)...
  33. ncbi request reprint Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression
    Lars Peters
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    J Acquir Immune Defic Syndr 50:457-63. 2009
    ..Conflicting data exist whether hepatitis C virus (HCV) affects the CD4 cell recovery in patients with HIV starting antiretroviral treatment...
  34. doi request reprint Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients
    D N Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Denmark
    Int J Tuberc Lung Dis 17:198-206. 2013
    ..To assess health care utilisation for patients co-infected with TB and HIV (TB-HIV), and to develop a weighted health care index (HCI) score based on commonly used interventions and compare it with patient outcome...
  35. ncbi request reprint Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study
    B T Røge
    Department of Infectious Diseases, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    HIV Med 5:344-51. 2004
    ..To investigate the interplay between resistance and adherence in the virological failure of three fundamentally different highly active antiretroviral therapy (HAART) regimens...
  36. doi request reprint Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study
    Nina Friis-Møller
    Copenhagen HIV Programme CHIP, University of Copenhagen Faculty of Health Science, Copenhagen, Denmark
    Eur J Cardiovasc Prev Rehabil 17:491-501. 2010
    ..Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients...
  37. ncbi request reprint Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression
    Thomas B Kristiansen
    Centre for Biological Sequence Analysis, Technical University of Denmark, Copenhagen, Denmark
    Scand J Infect Dis 37:890-901. 2005
    ..We hypothesize that certain patterns of mutations can cause a mutational deadlock where the evolutionary benefit of further resistance mutation is limited if the patient is kept on a stable HAART regimen...
  38. ncbi request reprint Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations
    Sofie Mathiesen
    Department of Infectious Diseases, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
    AIDS 18:1076-8. 2004
  39. doi request reprint The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection
    C da Cunha-Bang
    Center for Viral Diseases, Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Am J Transplant 13:458-66. 2013
    ..6 [95% CI:8.2-609.6]; p < 0.001). sGRMs emerged only following longer termed use of antiherpetic drugs and usually in recurrent CMV infection episodes. Risk of ganciclovir treatment failure was raised if an sGRM was detected...
  40. doi request reprint Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks
    J Kjaer
    Copenhagen HIV Programme, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    HIV Med 9:642-52. 2008
    ....
  41. doi request reprint Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke
    S W Worm
    Copenhagen HIV Programme, University of Copenhagen, Denmark
    J Infect Dis 205:535-9. 2012
    ..22; 95% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11)...
  42. doi request reprint Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina
    Daria N Podlekareva
    University of Copenhagen, Copenhagen HIV Programme, The Panum Institute Building 21 1, Blegdamsvej 3b, 2200 Copenhagen N, Denmark
    AIDS 23:2485-95. 2009
    ..Tuberculosis (TB) is a leading cause of death in HIV-infected patients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina...
  43. ncbi request reprint Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy
    Ole Kirk
    Copenhagen HIV Programme 044, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Antivir Ther 7:271-81. 2002
    ..To compare two analytic approaches to assess the virological effect of HAART according to the intention-to-treat (ITT) principle...
  44. ncbi request reprint Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial
    Ulrik Bak Dragsted
    Hvidovre University Hospital, Hvidovre, Denmark
    J Infect Dis 188:635-42. 2003
    ..A greater number of treatment-limiting adverse events were observed in the Idv/Rtv arm, relative to the Sqv/Rtv arm. In conclusion, Rtv-boosed Sqv and Idv were found to have comparable antiretroviral effects in the doses studied...
  45. pmc Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection
    Hans Henrik Larsen
    Hvidovre University Hospital, Copenhagen, Denmark
    Emerg Infect Dis 13:66-72. 2007
    ..0 (1.05-3.82) times more likely to harbor P. jirovecii than infants with a lower RTI. P. jirovecii may manifest itself as a self-limiting URTI in infants, predominantly those 1.5-4 months of age...
  46. ncbi request reprint Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study
    Ulrik Bak Dragsted
    Hvidovre University Hospital, Copenhagen, Denmark
    J Infect Dis 190:148-55. 2004
    ..Factors that determine the immunological response to highly active antiretroviral therapy (HAART) are poorly defined...
  47. ncbi request reprint Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study
    Nina Friis-Møller
    DAD Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark
    AIDS 17:1179-93. 2003
    ..To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies...
  48. doi request reprint Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART
    Daria Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Sciences, Denmark
    Scand J Infect Dis 40:908-13. 2008
    ..FI can be used as a clinical marker for disease progression and indirect indicator for initiation/changing cART in settings where laboratory facilities are limited...
  49. ncbi request reprint Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy
    Ole Kirk
    Coordinating Centre of EuroSIDA, Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Kettegaard Alle, 2650 Hvidovre, Denmark
    Ann Intern Med 137:239-50. 2002
    ..The safety of interrupting maintenance therapy for previous opportunistic infections other than Pneumocystis carinii pneumonia among patients with HIV infection who respond to potent antiretroviral therapy has not been well documented...
  50. ncbi request reprint The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results
    Daria Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Denmark
    Cent Eur J Public Health 16:99-105. 2008
    ..Strategies include creating scientific collaborations for HIV clinicians as well as teaching clinicians about the most advanced HIV management at clinically oriented courses held in eastern Europe...
  51. ncbi request reprint Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study
    Daria Podlekareva
    Hvidovre University Hospital, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
    J Infect Dis 194:633-41. 2006
    ..Limited data exist on factors predicting the development of opportunistic infections (OIs) at higher-than-expected CD4(+) cell counts in human immunodeficiency virus (HIV) type 1-infected adults...
  52. ncbi request reprint Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines
    Ole Kirk
    Copenhagen HIV Programme CHIP 044, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Curr Opin Infect Dis 17:33-7. 2004
    ..This review explores whether there have been changes in the reporting of randomized trials since the importance of continuous follow-up throughout the study period was initially raised 2 years ago...
  53. ncbi request reprint Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen
    Christian Holkmann Olsen
    Copenhagen HIV Programme, Section 044, Pavilion 1, DK 2650 Hvidovre, Denmark
    AIDS 19:319-30. 2005
    ..It is unknown whether the relationship between the HIV-RNA/CD4 cell count and risk of clinical disease continues to hold true for newer antiretroviral drugs approved without data from clinical endpoint trials...
  54. ncbi request reprint [Major breakthroughs in the medical treatment]
    Ole Kirk
    Epidemiklinikken M5132, Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 171:787-9. 2009
    ..The background for the breakthrough and the phases thereof are described and for comparison, the circumstances of major breakthroughs within other medical specialities are mentioned...
  55. ncbi request reprint A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial
    Ulrik B Dragsted
    Hvidovre University Hospital, Copenhagen, Denmark
    Antivir Ther 10:735-43. 2005
    ..To assess the rate of protocol-defined treatment failure and safety of lopinavir/ritonavir (LPV/r) and saquinavir/ritonavir (SAQ/r)...
  56. pmc Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)
    Signe W Worm
    Copenhagen HIV Programme, University of Copenhagen Faculty of Health Science, Bldg 21 1 Blegdamsvej 3B, DK 2200 Copenhagen, Denmark
    Circulation 119:805-11. 2009
    ..We investigated the impact of DM and preexisting CHD on the development of a new CHD episode among 33,347 HIV-infected individuals in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)...
  57. pmc Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study
    Signe W Worm
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    Diabetes Care 32:474-80. 2009
    ..Among HIV-infected individuals, we investigated whether any particular combinations of the components included in the definition of the metabolic syndrome are associated with a higher risk of cardiovascular disease (CVD)...
  58. ncbi request reprint A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors
    Ole Kirk
    Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Denmark
    Antivir Ther 8:595-602. 2003
    ..A triple-class HAART regimen may be associated with a better virological effect than conventional regimens, but may also lead to toxicity and more profound resistance...
  59. ncbi request reprint The case for indicator condition-guided HIV screening
    J V Lazarus
    Copenhagen HIV Programme, ISIM, Copenhagen University, Copenhagen, Denmark
    HIV Med 14:445-8. 2013
    ..Drawing on the work of the HIV Indicator Diseases across Europe Study (HIDES), new guidance brings together in one place a list of the conditions that should result in an HIV screening recommendation. ..
  60. ncbi request reprint Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital
    O Kirk
    Department of Infectious Diseases, Department of Clinical Microbiology, and Clinic of Respiratory Medicine, H S Hvidovre Hospital, University of Copenhagen
    Dan Med Bull 48:84-8. 2001
    ..We report on the outcome of a study of patients hospitalised with community acquired pneumonia (HCAP) at a Danish university hospital...
  61. ncbi request reprint Pneumocystis carinii major surface glycoprotein induces interleukin-8 and monocyte chemoattractant protein-1 release from a human alveolar epithelial cell line
    T L Benfield
    University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark
    Eur J Clin Invest 29:717-22. 1999
    ..The major surface glycoprotein (MSG) is an abundant, immunogenic glycoprotein located on the surface of Pneumocystis carinii. Little is known about the proinflammatory effects of MSG...
  62. pmc Heterogeneity and compartmentalization of Pneumocystis carinii f. sp. hominis genotypes in autopsy lungs
    J Helweg-Larsen
    Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark
    J Clin Microbiol 39:3789-92. 2001
    ....
  63. ncbi request reprint Independent risk of mechanical ventilation for AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia
    D Bang
    Department of Infections Diseases, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark
    Respir Med 95:661-5. 2001
    ..In conclusion, short-term mortality remained high after the introduction of adjunctive corticosteroid therapy. BAL neutrophilia may be a useful prognostic marker to identify patients at high risk of requiring mechanical ventilation...
  64. ncbi request reprint Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome
    Christian Ostergaard
    Division of Microbiology, Department of Antibiotic Resistance and Hospital Hygiene, Statens Serum Institut, Copenhagen, Denmark
    Scand J Infect Dis 36:14-9. 2004
    ..1 and above, the OR (95%CI) for fatal outcome was 11.9 (1.4-106), univariate logistic regression analysis, p = 0.026. In conclusion, CSF suPAR levels may be an important predictor for fatal outcome in purulent meningitis...
  65. ncbi request reprint Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials
    Ulrik S Justesen
    Department of Infectious Diseases, Odense University Hospital, Odense C, Denmark
    Basic Clin Pharmacol Toxicol 101:339-44. 2007
    ..Associations between high C(min) and toxicity were identified in the saquinavir arm; therefore, dose reductions may be appropriate in certain patients with C(min) several times above the minimum effective concentration...
  66. ncbi request reprint Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    AIDS 20:1141-50. 2006
    ..It is unknown if the CD4 cell count response differs according to antiretroviral drugs used in combination antiretroviral therapy (cART) in patients with maximal virological suppression [viral load (VL) < 50 copies/ml]...
  67. ncbi request reprint Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial
    Hans L Tillmann
    J Acquir Immune Defic Syndr 40:378-80. 2005
  68. ncbi request reprint Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort
    Deborah Konopnicki
    Division of Infectious Diseases, Saint Pierre University Hospital, Brussels, Belgium
    AIDS 19:593-601. 2005
    ..Whether hepatitis B (HBV) coinfection affects outcome in HIV-1-infected patients remains unclear...
  69. ncbi request reprint Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Badalona, Spain
    Antivir Ther 9:787-800. 2004
    ....
  70. pmc Current epidemiology of Pneumocystis pneumonia
    Alison Morris
    University of Southern California, Los Angeles, California, USA
    Emerg Infect Dis 10:1713-20. 2004
    ....
  71. ncbi request reprint Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
    Juan A Arnaiz
    Hospital Clinic IDIBAPS, University of Barcelona, Spain
    AIDS 17:831-40. 2003
    ....
  72. ncbi request reprint Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts
    Amanda Mocroft
    Royal Free and University College Medical School, London, UK
    Antivir Ther 12:325-33. 2007
    ....
  73. ncbi request reprint Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression
    Andrew N Phillips
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 18:1795-804. 2004
    ..It is currently unclear whether the tendency for viral rebound in patients with viral load < 50 copies/ml differs according to the specific drug regimen being used...
  74. ncbi request reprint [Decline in AIDS and death rates in the EuroSIDA study. An observational study]
    Ole Kirk
    H S Hvidovre Hospital, Copenhagen HIV Programme
    Ugeskr Laeger 166:2572-6. 2004
  75. ncbi request reprint Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lancet 364:51-62. 2004
    ..We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure...
  76. ncbi request reprint The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    Cancer 100:2644-54. 2004
    ....
  77. ncbi request reprint Starting highly active antiretroviral therapy: why, when and response to HAART
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    J Antimicrob Chemother 54:10-3. 2004
    ..There has been a switch to more conservative therapy recently, given concerns about toxicities and the difficulties of adhering to a complicated regimen long term...
  78. ncbi request reprint HIV survival benefit associated with earlier antiviral therapy
    Amanda Mocroft
    Ann Intern Med 140:578-9; author reply 579. 2004
  79. ncbi request reprint Combination antiretroviral therapy and the risk of myocardial infarction
    Nina Friis-Møller
    N Engl J Med 349:1993-2003. 2003
    ..It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction...
  80. ncbi request reprint Monitoring of long-term toxicities of HIV treatments: an international perspective
    Greg Bisson
    AIDS 17:2407-17. 2003
  81. ncbi request reprint Virological rebound after suppression on highly active antiretroviral therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 17:1741-51. 2003
    ..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response...
  82. ncbi request reprint Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    J Acquir Immune Defic Syndr 42:229-37. 2006
    ..Regional variations may identify differences in available antiretroviral drugs or patient management...
  83. ncbi request reprint Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study
    Rainer Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH 809a Zurich, Switzerland
    Arch Intern Med 166:1632-41. 2006
    ..An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases...
  84. ncbi request reprint Incidence of abacavir hypersensitivity reactions in euroSIDA
    Wendy P Bannister
    Royal Free and University College Medical School, London, UK
    Antivir Ther 13:687-96. 2008
    ..The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients...
  85. ncbi request reprint The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study
    Colette J Smith
    Royal Free and University College Medical School, London, UK
    AIDS 22:47-56. 2008
    ..This study investigated the incidence of pancreatitis and its association with antiretroviral therapy (ART), focussing on stavudine and didanosine...
  86. ncbi request reprint Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
    Matthias Egger
    Department of Social and Preventive Medicine, University of Bern, CH 3012 Bern, Switzerland
    Lancet 360:119-29. 2002
    ..The ART Cohort Collaboration, which includes 13 cohort studies from Europe and North America, was established to fill this knowledge gap...
  87. doi request reprint Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 22:367-76. 2008
    ..To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens...
  88. ncbi request reprint The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    Control Clin Trials 23:198-220. 2002
    ..This article describes the rationale supporting the trial in addition to reviewing the study design, coordination, and governance...
  89. ncbi request reprint Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis
    Massimo Puoti
    Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia, Brescia, Italy
    Antivir Ther 11:567-74. 2006
    ..The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied...
  90. pmc Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
    Caroline A Sabin
    Lancet 371:1417-26. 2008
    ..Our aim was to explore whether exposure to such drugs was associated with an excess risk of myocardial infarction in a large, prospective observational cohort of HIV-infected patients...
  91. doi request reprint Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model
    Andrew N Phillips
    HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
    Lancet 371:1443-51. 2008
    ..Our aim was to study the potential consequences of such monitoring strategies, especially in terms of survival and resistance development...
  92. ncbi request reprint Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1867-75. 2007
    ..To derive and validate a clinically applicable prognostic score for predicting short-term disease progression in HIV-infected patients taking combination antiretroviral therapy (cART)...
  93. ncbi request reprint Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free University College Medical School, London, UK
    Antivir Ther 13:177-87. 2008
    ..Exploratory analyses were performed to better understand the reasons for this observation...
  94. doi request reprint Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  95. doi request reprint Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008
  96. pmc State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary
    Steven K Grinspoon
    Circulation 118:198-210. 2008
  97. ncbi request reprint A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men
    Margaret May
    Department of Social Medicine, University of Bristol, UK
    Int J Epidemiol 36:1309-18. 2007
    ..We developed a prognostic model for CHD tailored to the changes in risk factors observed in patients starting HAART...
  98. ncbi request reprint Chronic renal failure among HIV-1-infected patients
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, and Department of Primary Care and Population Sciences, Royal Free and University College Medical Schools, Royal Free Campus, Rowland Hill Street, London, UK
    AIDS 21:1119-27. 2007
    ..The role of exposure to antiretrovirals in chronic renal failure (CRF) is not well understood. Glomerular filtration rates (GFR) are estimated using the Cockcroft-Gault (CG) or Modification of Diet in Renal Disease (MDRD) equations...
  99. ncbi request reprint Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    AIDS 21:721-32. 2007
    ..To estimate the extent of drug resistance accumulation in patients kept on a virologically failing regimen and its determinants in the clinical setting...
  100. ncbi request reprint Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
    Veronica Miller
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Frankfurt, Germany
    J Infect Dis 186:189-97. 2002
    ..10, P<.0001, respectively, for 4, 3, 2, 1, or no drugs vs. >or=5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment appears to decrease the risk of progression in immunocompromised patients...